Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04662840
Other study ID # MP-37-2021-6838
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date February 23, 2021
Est. completion date December 1, 2022

Study information

Verified date May 2023
Source McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a three-arm prospective double-blinded randomized comparative trial aimed at comparing results regarding knee pain improvement in patients with osteoarthritis (OA) of the knee awaiting total knee arthroplasty (TKA) by either a sham procedure, a geniculate artery embolization procedure or a geniculate nerve ablation procedure. Experienced interventional radiologists and anesthetists at the McGill University Health Centre (MUHC) and study affiliated centers will carry out all interventions. 72 consecutive subjects meeting the eligibility criteria, considered for knee replacement in the future. Patients will be randomized to receive either the embolization procedure, the nerve ablation procedure or a sham procedure. Monitoring of pain will be recorded using visual analog scales, pain medication use, and Western Ontario and McMaster Universities Arthritis Index (WOMAC) and osteoarthritis knee and hip quality of life questionnaire (OAKHQOL) questionnaires over a period of 1 year post-treatment or up to the time of surgery. Pain and recovery post surgery will be monitored as well in patients who do get the Total Knee Arthroplasty (TKA) before the 1 year mark.


Description:

This is a three-arm prospective double-blinded randomized comparative trial. Experienced interventional radiologists and anesthetists at the MUHC and study affiliated centers will carry out all interventions. - 72 consecutive subjects meeting the eligibility criteria, considered for knee replacement in the future. - Patients will be referred for consideration for the study by specialized arthroplasty orthopedic surgeons from their osteoarthritis clinic at St-Mary's hospital. - Prospective patients interested will be referred to the interventional radiology clinic at the MUHC for discussion of the procedures and of the study and recruitment. - Consent will be obtained from all patients. - Patients who accept to participate and fit the criteria will be randomized to receive either the embolization procedure, the nerve ablation procedure or a sham procedure. They will fill out the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and osteoarthritis knee and hip quality of life questionnaire (OAKHQOL) questionnaires as well the Visual Analog Scale (VAS) for pain which will serve as baseline. - They will then be contacted by the appropriate service to schedule the procedure. - All embolization or nerve ablation procedures will be performed by either a qualified interventional radiologist or anesthetist. Patients will be informed that they will not know which procedure they will receive. A barrier will be placed to shield them from visualizing the procedure and, for both procedures and sham procedure, skin freezing, and post-procedural bandages will be applied to the groin and in the skin around the knee. The patients will be informed that the procedures can take similar time between 15 minutes and 1 hr and that timing is variable between patients. They will also be informed that pain sensation around the knee can be similar between procedures. For all procedures, a written scenario (words and manipulations of the skin) will be followed such that all patients have the impression they are getting the same thing despite some having only the sham, others the embolization, and others the denervation. At the end of all procedures, patients will be transferred to the recovery room as per routine for interventional radiology procedures. Recovery room nurses will not know which of the procedures the patient had. They will be informed to look out for possible complications from either procedure. Patients will be informed that they must remain with their legs still for 3hrs after the procedure to prevent bleeding from the possible puncture in the artery that is necessary for the embolization procedure. No procedure specific technical discussion regarding the procedure will occur during the procedures to suggest what was done, only the common scenario will be followed. All this will be done in an attempt to blind the patient as much as possible. Blinding will be lifted for once the patient has completed the study. There is a final questionnaire to be filled out by the patient and physician at which point the patient will be informed of what procedure they received. - The patients will be offered IV analgesia using midazolam and fentanyl during the procedure at regular intervals and the patients will be left to decide if they think it is necessary or not. - Analgesics will be provided as per set orders during the recovery period in the post-procedural recovery room. Pain scales and medications provided are routinely registered in Post-Anesthesia Care Unit (PACU) documents and this data will be collected - The patient will be discharged home with standard prescriptions for 2-3 days of post-procedural home analgesics and then will restart their routine pain control regimen they have been using. - After the procedure, while at home, the patient will fill out paper or on-line confidential surveys (only study number on the survey, no patient identifying information) of routine medications used, WOMAC questionnaires and a VAS at regular interval (1d, 1wk, 2wks, 1m, 2m, 3m, 6m, 9m, 12m and if the patient has surgery at 1wk, 2wk, 1m, 2m, and 3m post-surgery). In addition, the OAKHQOL questionnaire will be filled out at 1m, 6m, and 12m and if the patient has surgery a 3m after surgery. The patients will be contacted by phone to make sure they remember to fill these out at the correct intervals. If they have chosen to use the paper forms, they will be collected in a pre-stamped envelope to send back to us at the 12m mark. - A patient will be considered to have completed the study after 12m without knee surgery or 3m after a knee replacement surgery, whichever occurs first. - Data will be gathered, stored, and analyzed. - Data collected will include demographics, relevant medical history, vital signs, which procedure was performed, as well as the use of IV and oral analgesics, visual analog pain scores (VAS), WOMAC, and OAKHQOL questionnaires, X-rays performed during routine follow-ups at the orthopedic surgery clinic will be graded as per International Knee Documentation Committee (IKDC) grading system. - Other than the initial visit aimed at getting consent and randomizing the patients and the procedures themselves, any research specific patient encounters scheduled in this study will be done by phone, unless the patient requests otherwise.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 1, 2022
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients diagnosed with knee osteoarthritis awaiting knee replacement surgery (expected to be more than a 3m waiting time) presenting with knee pain that patients consider unsatisfactorily managed by routine oral pain medications or cannot tolerate such medications. 2. Patients 18 y.o. or older Exclusion Criteria: 1. Patients who are expected to have TKA surgery within 3 months. 2. Patients in whom the anatomy prevents either procedure - Vascular anatomy that prevents vascular access such as occluded vasculature to the leg - Skin or deep infection that would prevent placement of needles 3. Suspected concomitant infected knee joint or other signs of infections such as fever 4. Patients with uncorrectable abnormal coagulation status (INR >1.5 and plt < 50,000 without use of anticoagulation agents) 5. Patients who have known severe allergy to the anesthetic agent or contrast 6. Patients with pre-existing conditions, which, in the opinion of the investigator, interfere with the conduct of the study 7. Patients who are uncooperative, cannot follow instructions, or who are unlikely to comply with follow-up appointments or fill-out the post-procedural pain questionnaires 8. Patients with mental state that may preclude completion of the study procedure or be unable to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Geniculate artery embolization
Under fluoroscopic guidance and angiographic imaging, a microcatheter is used to select all the arteries feeding the affected knee and Embosphere (100-300um) particles are injected to obtaining pruning of the hypervascular tissues arteries.
Geniculate nerve ablation
Under fluoroscopic guidance, a Cool-tip RFA ablation needle is advanced such that it touches the femur at the condylar convexity on each side and the tibia at the tibial plateau convexity on the medial side. The ablation is performed to obtain an approximate zone of ablation of 2cm.
Skin infiltration of local anesthetic at groin and knee
Freezing of the skin will be performed at the groin (as prior to an arterial access for embolization procedure) and at three areas around the knee (as prior to insertion of the ablation needles for nerve ablation procedure).

Locations

Country Name City State
Canada McGill University Health Centre Montreal Quebec
Canada McGill University Health Centre Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
McGill University Health Centre/Research Institute of the McGill University Health Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in knee pain post geniculate artery embolization versus nerve ablation vs sham Assessment of changes in pain Visual Analog Scale (VAS - scale 0-10 with 10 being the highest degree of pain) scores between groups having undergone embolization versus ablation versus sham procedures 1 year
Primary Changes in knee pain/functionality in geniculate artery embolization versus nerve ablation vs sham Assessment of changes in pain and functionality score using Western Ontario and McMaster Universities Arthritis Index scores (WOMAC - scale 0-96 with 96 being the most worse pain/functionality) between groups having undergone embolization versus ablation versus sham procedures 1 year
Primary Changes in pain medication use in geniculate artery embolization versus nerve ablation vs sham Assessment in changes in dose (mg) of anti-inflammatory pain meds used between groups having undergone embolization versus ablation versus sham procedures 1 year
Secondary Comparison of incidence of complications in geniculate artery embolization vs geniculate nerve ablation vs sham Assessment of difference in incidence of serious complications (Grade C-E as per Society of Interventional Radiology (SIR) adverse event grading) in geniculate artery embolization vs geniculate nerve ablation vs sham groups 1 year
Secondary Changes in VAS pain scores after TKA in geniculate artery embolization vs geniculate nerve ablation vs sham Assessment of changes in pain (VAS - scale 0-10 with 10 being the highest degree of pain) scores post TKA between groups having undergone embolization vs geniculate ablation vs sham procedures 3 months post-surgery
Secondary Changes in quality of life in geniculate artery embolization versus nerve ablation vs sham Assessment of changes in functionality osteoarthritis knee and hip quality of life scores (OAKHQOL - scale 43 quality of life items scored from 0-10 with 10 being the worse symptoms) between groups having undergone embolization versus ablation versus sham procedures 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03895489 - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses N/A
Completed NCT03660943 - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain Phase 3
Completed NCT04531969 - Comparison of Outpatient and Inpatient Spa Therapy N/A
Completed NCT02848027 - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment Phase 3
Completed NCT05160246 - The Instant Effect of Kinesiology Taping in Patients With Knee OA N/A
Recruiting NCT06080763 - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed NCT03643588 - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain N/A
Active, not recruiting NCT05100225 - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Phase 2
Active, not recruiting NCT04061733 - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis N/A
Completed NCT04051489 - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting NCT05546541 - Epidemiology and Nutrition
Recruiting NCT05447767 - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg Phase 2
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Not yet recruiting NCT03225911 - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis N/A
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Completed NCT05703087 - Positive Cueing in Knee Arthroplasty. N/A
Not yet recruiting NCT06042426 - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population Phase 4
Completed NCT02905747 - The Effect of Medical Exercise Therapy on Pain, Function and Physical Activity in Patients With Knee Osteoarthritis N/A
Completed NCT03037489 - A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients Phase 2
Completed NCT02944448 - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Phase 2